#China #Shanghai #Kexing Biopharm #CPHI & PMEC #RD Innovation Award

The Essence of Innovation at CPHI & PMEC China 2026

From June 16 to 18, 2026, the annual CPHI & PMEC China exhibition held at the Shanghai New International Expo Center showcased the latest advancements in the pharmaceutical industry. Among the prominent participants was Kexing Biopharm, a leading biopharmaceutical company, which displayed its extensive pipeline of self-developed drugs and garnered significant accolades at the event.

Kexing Biopharm's exhibition featured over 30 innovative products designed for global markets. The company's presence in areas such as oncology, autoimmune conditions, and metabolic diseases highlights its diverse portfolio. Notably, key products like albumin-bound paclitaxel and bevacizumab attracted considerable interest from attendees.

Recognition for Research and Development

Kexing Biopharm's commitment to research and development was further validated when the company received the RD Innovation Award during the CPHI awards ceremony. This prestigious recognition highlights the company’s breakthroughs and innovative contributions to the pharmaceutical sector. The selection criteria for this award involve a multifaceted evaluation process that considers clinical translation successes, technological innovations, and market implications.

As the company showcased several promising drug pipelines—such as GB18 for cancer cachexia and GB19/GB26 for systemic lupus erythematosus—its commitment to addressing significant health challenges has become evident. Clinical developments for two Phase III programs, focusing on long-acting GC and interferon inhalation solutions, further underscore Kexing Biopharm's robust research capabilities.

Engaging Forums and International Networking

In addition to showcasing its products, Kexing Biopharm actively participated in various forums and roundtable discussions aimed at fostering global expansion in the pharmaceutical landscape. These discussions centered on pivotal topics such as the international commercialization of Chinese biopharmaceuticals. The company's Business Development (BD) team facilitated insightful dialogues, providing essential perspectives that improve Kexing’s strategic pathways into international markets.

On the evening prior to the commencement of the exhibition, Kexing Biopharm organized a networking event that welcomed partners and customers from multiple countries. This gathering enabled the participants to delve into discussions about market dynamics and future opportunities for collaboration, laying the groundwork for potential partnerships going forward.

Looking Toward the Future

CPHI serves as an essential platform for Kexing Biopharm to not only showcase its innovative products but also to forge critical connections within the global pharmaceutical community. As the company continues to strengthen its international presence, it remains focused on collaborating with diverse partners to deliver high-quality products worldwide.

In conclusion, Kexing Biopharm’s participation in CPHI & PMEC China 2026 illustrates its unwavering commitment to innovation and global health. As the pharmaceutical landscape evolves, Kexing is poised to leverage its strengths and pioneer solutions that meet the demands of an increasingly interconnected market.